Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Pulmonology

   News

   Conferences

   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 Headlines:

 
 

 

Back to Chest Drug index

Back to Corticosteroids

Name: Triamcinolone

  Asthma News
 

Xolair reduced the rate of hospital emergency visits by 44% in patients with inadequately controlled asthma.

 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version
 
related discussion
 

  Related
 
 

Asthma

 
   

Pregnancy Category C

Drug classes

  • Corticosteroid (intermediate acting)
  • Glucocorticoid
  • Hormonal agent

Therapeutic actions

Enters target cells and binds to cytoplasmic receptors, thereby initiating many complex reactions that are responsible for its anti-inflammatory and immunosuppressive effects.

Indications

  • Hypercalcemia associated with cancer (systemic)
  • Short-term management of various inflammatory and allergic disorders, such as rheumatoid arthritis, collagen diseases (eg, SLE), dermatologic diseases (eg, pemphigus), status asthmaticus, and autoimmune disorders
  • Hematologic disorders: thrombocytopenia purpura, erythroblastopenia
  • Ulcerative colitis, acute exacerbations of mutiple sclerosis, and palliation in some leukemias and lymphomas
  • Trichinosis with neurologic or myocardial involvement
  • Pulmonary emphysema with bronchial spasm or edema; diffuse interstitial pulmonary fibrosis; with diuretics in CHF with refractory edema and in cirrhosis with refractory ascites
    Postoperative dental inflammatory reactions
  • Arthritis, psoriatic plaques, and so forth (intra-articular, soft-tissue administration)
  • Control of bronchial asthma requiring corticosteroids in conjunction with other therapy (respiratory inhalant)
  • To relieve inflammatory and pruritic manifestations of dermatoses that are steroid responsive (dermatologic preparations)

Contraindications/cautions

Contraindicated in the presence of infections, especially tuberculosis, fungal infectons, amebiasis, vaccinia and varicella, and antibiotic-resistant infections; lactation; allergy to tartrazine in 8-mg oral tablets marketed under the brand name Kenacort.

Use caution in the presence of pregnancy (teratogenic in preclinical studies); kidney or liver disease, hypothyroidism, ulcerative colitis with impending perforation, diverticulitis, active or latent peptic ulcer, inflammatory bowel disease, CHF, hypertension, thromboembolic disorders, osteoporosis, convulsive disorders, diabetes mellitus.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Adverse effects

Effects depend on dose, route, and duration of therapy.

  • CNS: Vertigo, headache, paresthesias, insomnia, convulsions, psychosis, cataracts, increased intraocular pressure, glaucoma (long-term therapy)
  • GI: Peptic or esophageal ulcer, pancreatitis, abdominal distention, nausea, vomiting, increased appetite, weight gain (long-term therapy)
  • CV: Hypotension, shock, hypertension and CHF secondary to fluid retention, thromboembolism, thrombophlebitis, fat embolism, cardiac arrhythmias
  • MS: Muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, spontaneous fractures (long-term therapy)
  • Hypersensitivity: Hypersensitivity or anaphylactoid reactions
  • Endocrine: Amenorrhea, irregular menses, growth retardation, decreased carbohydrate tolerance, diabetes mellitus, cushingoid state (long-term effect), increased blood sugar, increased serum cholesterol, decreased T3 and T4 levels, hypothalamic-pituitary-adrenal (HPA)
    suppression with systemic therapy longer than 5 d
  • Electrolyte imbalance: Na+ and fluid retention, hypokalemia, hypocalcemia
  • Other: Immunosuppression, aggravation, or masking of infections; impaired wound healing; thin, fragile skin; petechiae, ecchymoses, purpura, striae; subcutaneous fat atrophy Intra-articular
  • Local: Osteonecrosis, tendon, rupture, infection

Intralesional (face and head)

  • Local: Blindness (rare)

Respiratory Inhalants

  • Local: Oral, laryngeal, and pharyngeal irritation; fungal infections

Topical Dermatologic Ointments, Creams, Sprays

  • Local: Local burning, irritation, acneiform lesions, striae, skin atrophy
  • Systemic absorption of dermatologic preparations can lead to HPA suppression (see above), growth retardation in children, and other systemic adverse effects. Children may be at special risk of systemic absorption because of their larger skin surface to body weight ratio.
 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.